Chise Profile picture
Dec 30, 2021 14 tweets 6 min read Read on X
Immunity is more than just neutralizing antibodies.

Why? Because MOST of your T-cell responses from vaccination or previous infection STILL recognize Omicron.

Let’s talk about that!🧵
Immunological memory consists of antibodies, memory B-cells, memory CD8+ T-cells, and memory CD4+ T-cells. These responses are what give us enduring protection even against newly emerging SARS-CoV-2 variants.
Immunological memory is probably the most important feature of immunity as it allows us to better respond when the threat is encountered a second time. Against SARS-CoV-2, it helps to determine protection against reinfection, disease risk, and vaccine efficacy.
As long as your T-cells still recognize this virus and inform your B-cells they need to get to work and adjust to make antibodies to be better “fit” you’re protected. Imagine your B-cells are your sword that need sharpening every now and again and your T-cells are your shield.
The term infection refers to the virus entering and being detectable in your system regardless of whether OR NOT it makes you sick, whereas the term illness refers to the virus entering, being detectable in your system AND making you sick. It it important not to conflate the two.
T-cell epitopes in natural infection? Their analysis of the full proteome here showed that on average 98% of CD8+ and 95% of CD4+ epitopes were totally conserved.
T-cell epitopes and vaccination? Here is the analysis of spike-only data. Since many variant mutations are in spike, naturally a higher number of mutated T-cell epitopes. On average 94% of CD8+ and 91% of CD4+ epitopes were still totally conserved.
When they get to Omicron presumably because of the higher number of mutations, the fraction of CD8+ epitopes that are 100% conserved drops significantly to 95% for CD8+ and 88% for CD4+ whole proteome. Guess what? Still VERY HIGH conservation.
“Despite Omicron's extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T-cell response, induced by vaccination or natural infection, cross-recognises the variant.”
medrxiv.org/content/10.110…
Researchers here assessed the ability of T-cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients. They found that 70-80% of the CD4+ and CD8+ T-cell response to spike was maintained.
Moreover, the magnitude of Omicron cross-reactive T-cells was similar to that of the Beta and Delta variants, DESPITE Omicron harbouring considerably more mutations.
Indeed, South Africa has reported a lower risk of hospitalization and severe disease compared to the previous Delta wave. Cross-reactive T-cell responses acquired through vaccination or infection may contribute to these apparent milder outcomes for Omicron.
You can read more here papers.ssrn.com/sol3/papers.cf… and reuters.com/business/healt…. The resilience of T-cell response demonstrated here also bodes well in the event that more highly mutated variants emerge in the future. MAKE SURE YOU ARE PROTECTED. DON’T WALK AROUND IMMUNE NAIVE.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Jun 27
THIS IS HUGE! Researchers at JHU have identified the Aplp1 protein, which facilitates the spread of harmful alpha-synuclein proteins in the brain as a novel therapeutic target for Parkinson’s disease AND a potential therapy using an EXISTING FDA-approved cancer drug.🧵⬇️
In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the spread of Parkinson’s disease-causing alpha-synuclein.
Read 15 tweets
Jun 21
THIS IS HUGE! For the FIRST time, an HIV PrEP drug candidate in the form of a twice-yearly subcutaneous shot has shown ZERO infections in a late-stage Phase III trial. Lenacapavir was 100% effective at preventing HIV in MORE THAN 2,000 participants.

Let’s talk about that!🧵⬇️
These results come from the PURPOSE 1 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in women and adolescent girls ages 16 to 25 in South Africa and Uganda. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the
Read 14 tweets
Jun 11
THIS IS HUGE! Researchers at the University of Illinois have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections (MORE THAN 130 multidrug-resistant bacterial strains, in fact) while sparing the gut microbiome!

Let’s talk about that!🧵⬇️
The findings were recently published in Nature.


The study looked at the development of an antibiotic that targets gram-negative bacteria without disturbing the gut microbiome.nature.com/articles/s4158…
Researchers identified the antibiotic lolamicin, which disrupts a particular system called the Lol lipoprotein transport system.
ncbi.nlm.nih.gov/pmc/articles/P…
Read 13 tweets
Jun 7
THIS IS HUGE! A major trigger in inflammatory bowel disease (IBD) and related conditions has been identified, and existing drugs CAN stamp it out, in what scientists call a "massive step" in successfully treating these debilitating chronic conditions. Let’s talk about that! 🧵⬇️
Researchers at the Francis Crick Institute, in collaboration with University College London (UCL) and Imperial College London (ICL), have uncovered a problem gene enhancer that stimulates action along a specific biological pathway that causes IBD inflammation.
Until now, our incomplete knowledge of what drives IBD has made it incredibly hard to find a 'one-size-fits-all' medical intervention.

The findings were published recently in Nature.
nature.com/articles/s4158…
Read 15 tweets
May 28
HOW COOL IS THIS? A vaccine for honeybees? More likely than you think! Not only did the vaccine protect bees from a fatal BACTERIAL disease, it ALSO protected them against from a VIRAL disease spread by varroa mites! Now that’s a BUZZWORTHY solution! 🐝

Let’s talk about that! 🧵 Honeybees are under stress from pesticides, mites and a variety of diseases. Now, a new vaccine aimed at protecting bees from a serious bacterial infection may do double duty by warding off a virus.
The first vaccine designed for insects may make honeybees healthier overall. Honeybee hives vaccinated against a bacterial disease had much lower levels of an unrelated viral disease than did unvaccinated hives.
frontiersin.org/articles/10.33…
Researchers at Dalan, based in Athens, Georgia designed the bee vaccine to protect against American foulbrood- a fatal disease caused by a spore-forming bacterium called Paenibacillus larvae. Adult bees don’t get sick but can spread spores in the hive, where the disease infects
Read 13 tweets
May 22
THIS IS HUGE! A new study shows nanoparticles fashioned from the cowpea mosaic virus demonstrated remarkable success in improving survival rates AND suppressing the growth of metastatic tumors across VARIOUS cancer models including colon, ovarian, and breast cancer!🧵⬇️
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.

The findings were published recently in Advanced Science.
onlinelibrary.wiley.com/doi/10.1002/ad…
The treatment, composed of nanoparticles fashioned from the cowpea mosaic virus showed remarkable success in improving survival rates and suppressing the growth of metastatic tumors across various cancer models. Similar outcomes were also observed by the team when the treatment
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(